Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

720.55 +16.25 (+2.31%)
Streaming Delayed Price Updated: 1:23 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
News headline image
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder ↗
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results. 
Via Benzinga
News headline image
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull ↗
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation. 
Via Stocktwits
Topics Supply Chain
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss ↗
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said. 
Via Stocktwits
Topics Death
News headline image
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025 ↗
These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching. 
Via The Motley Fool
Topics Stocks
News headline image
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
From 23andMe, Inc.
Via GlobeNewswire
News headline image
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025 ↗
Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you. 
Via The Motley Fool
News headline image
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor? ↗
Via The Motley Fool
News headline image
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies ↗
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity. 
Via Benzinga
News headline image
Regeneron Pharma Shares Rise Over 3% After Key Signal ↗
A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Monday? ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season ↗
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group. 
Via Benzinga
News headline image
23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer ↗
Regeneron previously won 23andMe at auction. But now the company wants to reopen bidding with an offer from its former CEO. 
Via Investor's Business Daily
Topics Bankruptcy Lawsuit
News headline image
Why Regeneron Is Falling And Why You Should Avoid It ↗
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN. 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target ↗
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce. 
Via Benzinga
News headline image
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response ↗
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026. 
Via Benzinga
News headline image
Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500 ↗
Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the... 
Via Stocktwits
Topics Death
News headline image
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip ↗
Via The Motley Fool
Topics Economy
News headline image
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN) ↗
US stocks ended May cautiously after strong monthly gains, as renewed trade tensions with China stirred market uncertainty. 
Via Chartmill
Topics World Trade
News headline image
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? ↗
11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.